Shamburg News · 8-K filed Nov 5, 2026, 4:01 PM EST
BridgeBio Oncology Therapeutics' Chief Medical and Development Officer to resign
BBOT · BridgeBio Oncology Therapeutics, Inc.
- Leadership change
- Materiality: high
On October 30, 2026, Yong Ben, M.D., M.B.A. gave notice of his resignation as Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc., effective January 8, 2027. The filing states the resignation was not due to any disagreement with the Company regarding its operations, policies or practices.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001193125-26-449722.
Written from the filing by Shamburg Markets. Figures are as reported by the company.